US11638741B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11638741-B2 |
| Application number | US-201916688128-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2019 |
| Priority date | Nov 19, 2018 |
| Publication date | May 2, 2023 |
| Grant date | May 2, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a composition for preventing or treating cancer, a composition for inhibiting the metastasis of cancer, and the like, including TFG nanoparticles or TFMG nanoparticles, and more particularly, to a composition exhibiting effects of treating cancer, effects of inhibiting the metastasis of cancer, and the like by normalizing blood vessels inside a tumor.
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer, comprising a step of administering, to an individual having lung cancer, a composition comprising, as an active ingredient, nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 1 or nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 2, wherein the composition normalizes blood vessels inside cancer tissues by alleviating hypoxic conditions and increasing pericytes in cancer tissues. 2. The method of claim 1 , wherein the composition inhibits the proliferation, metastasis, and recurrence of cancer or resistance to anticancer therapy. 3. The method of claim 1 , wherein the individual is a patient undergoing anticancer therapy. 4. The method of claim 3 , wherein the anticancer therapy is radiation therapy or anticancer agent therapy. 5. A method for treating cancer, comprising a step of administering, to an individual having lung cancer, a composition comprising an anticancer agent and, as an active ingredient, nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 1 or nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 2, wherein the composition improves treatment effects of an anticancer agent through normalization of blood vessels inside cancer tissues by alleviating hypoxic conditions and increasing pericytes in cancer tissues. 6. A method for inhibiting the metastasis of lung cancer, comprising a step of administering, to an individual, a composition comprising, as an active ingredient, nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 1 or nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 2, wherein the composition normalizes blood vessels inside cancer tissues by alleviating hypoxic conditions and increasing pericytes in cancer tissues. 7. The method of claim 6 , wherein the metastasis is metastasis into the lungs or the lymph nodes. 8. A method of alleviating hypoxic conditions and increasing pericytes in cancer tissues of an individual having lung cancer, comprising administering a composition to the individual, wherein the composition comprises nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 1 or nanoparticles comprising an amino acid sequence represented by SEQ ID NO: 2.
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
specific for metastasis · CPC title
Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title
Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.